Business Context and Reporting Period
Company: EXICURE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2021
Event: Announcement of a virtual R&D Day to discuss the company's neuroscience pipeline, specifically its lead program for Friedreich's Ataxia (FA). The event was scheduled for January 7, 2021, from 9:00 am to 10:30 am ET.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding an upcoming corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates are reported in this document. The filing serves solely to disclose the timing and availability of the R&D Day webcast and its accompanying slide presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The company intends to present updates on its neuroscience pipeline during the R&D Day. The slide presentation is attached as Exhibit 99.1.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth by specific reference.
Risks/Contingencies: No specific risks or contingencies are detailed in this 8-K filing.
Investor Verification Checklist
- Verify the content of the R&D Day slide presentation (Exhibit 99.1) for specific data on the Friedreich's Ataxia program.
- Confirm the availability of the webcast on the company's website within the 30-day window following the event.
- Review subsequent filings (e.g., 10-K or 10-Q) for actual financial performance metrics, as this 8-K contains no financial data.